{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:59:40Z","timestamp":1790099980416,"version":"4.0.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"name":"J McNamara Retina Research Fund"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To determine factors associated with persistent vision loss among eyes with nonproliferative diabetic retinopathy and diabetic macular edema who return to care after loss to follow-up (LTFU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study was conducted at the Wills Eye Hospital\/Mid Atlantic Retina between January 1st, 2015 and January 1st, 2023. Patients were included if they met the following study inclusion criteria (1) \u22651 anti\u2013vascular endothelial growth factor injection before LTFU; (2) history of LTFU for &gt;6 months; (3) returned for care with \u226512 months of follow-up after LTFU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 169 eyes of 169 patients met our inclusion criteria. Approximately 38% of eyes (N = 64\/169) worsened after returning to care, with \u226510-letter decline in visual acuity compared with their pre-LTFU visit. At 12 months postreturn, 27.2% (N = 46\/169) had a persistent \u226510-letter decrease in visual acuity from their pre-LTFU baseline. On multivariable analysis, White race (OR 0.42, 95% CI: 0.20\u20130.92,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03) was associated with decreased likelihood of \u226510-letter loss at the 12-month follow-up visit. Visual acuity at time of return (OR 6.47, 95% CI: 1.96\u201321.33,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002) was also associated with vision loss at the 12-month visit. Increasing central foveal thickness at time of return (OR 1.004, 95% CI: 1.001\u20131.007,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.012) was the only factor associated with a \u226510-letter loss at the return visit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Approximately 1\/4th of eyes had persistent vision loss at 1-year despite resumption of treatment. Race and visual acuity upon return after LTFU were associated with vision loss at the 12-month visit. Increased macular edema was associated with vision loss at return visit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004892","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:00:26Z","timestamp":1780063226000},"page":"1748-1758","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["FACTORS ASSOCIATED WITH PERSISTENT VISION LOSS IN EYES WITH DIABETIC MACULAR EDEMA AND NONPROLIFERATIVE DIABETIC RETINOPATHY AFTER LOST-TO-FOLLOW-UP"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-2837","authenticated-orcid":false,"given":"Sidra","family":"Zafar","sequence":"first","affiliation":[{"name":"Mid Atlantic Retina, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Momenaei","sequence":"additional","affiliation":[{"name":"Mid Atlantic Retina, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kim","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Cheslow","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselind L.","family":"Ni","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishan","family":"Kasat","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raziyeh","family":"Mahmoudzadeh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, VCU Health, Richmond, Virginia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hsu","sequence":"additional","affiliation":[{"name":"Mid Atlantic Retina, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania;"},{"name":"The Vickie and Jack Farber Vision Research Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260922","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis"},{"key":"R2-20260922","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamaophthalmol.2022.0052","article-title":"Trends in prevalence and treatment of diabetic macular edema and vision-threatening diabetic retinopathy among medicare part B fee-for-service beneficiaries","volume":"140","author":"Lundeen","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R3-20260922","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ophtha.2025.01.022","article-title":"Twenty-year trends in prevalence and incidence of diabetic retinal disease","volume":"132","author":"VanderBeek","year":"2025","journal-title":"Ophthalmology"},{"key":"R4-20260922","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of anti\u2013vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R5-20260922","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","article-title":"Compliance and adherence of patients with diabetic macular edema to intravitreal anti\u2013vascular endothelial growth factor therapy in daily practice","volume":"38","author":"Weiss","year":"2018","journal-title":"Retina"},{"key":"R6-20260922","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3928\/23258160-20180221-06","article-title":"Appointment compliance in patients with diabetic macular edema and exudative macular degeneration","volume":"49","author":"Jansen","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R7-20260922","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ajo.2020.06.040","article-title":"The short-term effect of a single lapse in anti\u2013vascular endothelial growth factor treatment for diabetic macular edema within routine clinical practice","volume":"219","author":"Yalamanchili","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R8-20260922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2021.06.028","article-title":"Outcomes of eyes with diabetic macular edema that are lost to follow-up after anti\u2013vascular endothelial growth factor therapy","volume":"233","author":"Matsunaga","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R9-20260922","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jamaophthalmol.2021.4103","article-title":"Lapses in care among patients assigned to ranibizumab for proliferative diabetic retinopathy: a post hoc analysis of a randomized clinical trial","volume":"139","author":"Maguire","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R10-20260922","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/24741264241305123","article-title":"Predictors of vision loss after lapse in antivascular endothelial growth factor treatment in patients with diabetic macular edema","volume":"9","author":"Chalasani","year":"2025","journal-title":"J VitreoRetinal Dis"},{"key":"R11-20260922","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.oret.2018.11.002","article-title":"Loss to follow-up after intravitreal anti\u2013vascular endothelial growth factor injections in patients with diabetic macular edema","volume":"3","author":"Gao","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R13-20260922","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2337\/diacare.22.5.779","article-title":"Black-white differences in risk of developing retinopathy among individuals with type 2 diabetes","volume":"22","author":"Harris","year":"1999","journal-title":"Diabetes Care"},{"key":"R14-20260922","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archopht.118.6.819","article-title":"Causes of blindness and visual impairment in a population of older Americans: the Salisbury eye evaluation study","volume":"118","author":"Munoz","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R15-20260922","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1475-6773.2004.00297.x","article-title":"Monitoring visual status: why patients do or do not comply with practice guidelines","volume":"39","author":"Sloan","year":"2004","journal-title":"Health Serv Res"},{"key":"R16-20260922","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.ophtha.2004.03.002","article-title":"Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study","volume":"111","author":"Varma","year":"2004","journal-title":"Ophthalmology"},{"key":"R17-20260922","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamaophthalmol.2024.0974","article-title":"Place, race, and lapses in diabetic retinopathy care","volume":"142","author":"Tang","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R18-20260922","doi-asserted-by":"crossref","first-page":"100295","DOI":"10.1016\/j.xops.2023.100295","article-title":"Health disparities in lapses in diabetic retinopathy care","volume":"3","author":"Cai","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"R19-20260922","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections","volume":"125","author":"Obeid","year":"2018","journal-title":"Ophthalmology"},{"key":"R20-20260922","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0002-9394(74)90010-5","article-title":"Blindness caused by diabetic retinopathy","volume":"78","author":"Kahn","year":"1974","journal-title":"Am J Ophthalmol"},{"key":"R21-20260922","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s11892-013-0421-9","article-title":"Race\/ethnic difference in diabetes and diabetic complications","volume":"13","author":"Spanakis","year":"2013","journal-title":"Curr Diab Rep"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:00:31Z","timestamp":1790096431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004892","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}